SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

Ī

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

l										
	OMB Number:	3235-0287								
	Estimated average burden									
	hours per response:	0.5								

1. Name and Addres	1 0	rson*	2. Issuer Name and Ticker or Trading Symbol Unity Biotechnology, Inc. [UBX]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Burow Kristi	<u>na</u>		<u>Onicy Diotectinology, nic.</u> [ODX]	X	Director	10% Owner			
1	(First) (Middle) ENTURE PARTNERS GINS RD, SUITE 1025		3. Date of Earliest Transaction (Month/Day/Year) 05/02/2018		Officer (give title below)	Other (specify below)			
8/55 W. HIGGI	NS RD, SUITE	1025	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	ng (Check Applicable				
(Street) CHICAGO	IL	60631	_	X	Form filed by One Re Form filed by More that Person	9			
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	ate Execution Date,		ction Instr.				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (1 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$17	05/02/2018		A		40,678		(1)	05/01/2028	Common Stock	40,678	\$0	40,678	D	

Explanation of Responses:

1. The shares underlying the option shall vest as to 1/3rd of the underlying shares on each anniversary of May 2, 2018, subject to the Non-Employee Director continuing to serve on the Board through such vesting date.

<u>/s/ Tamara L. Tompkins,</u> Attorney-in-Fact for Kristina

** Signature of Reporting Person

05/04/2018

Burow

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.